GPR84 and esophageal cancer: Quin et al. demonstrated that the blockade of GPR84 inhibited the tumor progression of orthotropic esophageal cancer mouse models as well as subcutaneous LLC and B16 models by remodeling the immunosuppressive tumor microenvironment.